---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-050545"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T04:58:44.752669+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved

## Summary
- Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).
- 84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.
- Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.
- Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application.

## SEC filing metadata
- accession: 0001628280-24-050545
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/0001628280-24-050545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/sgmo-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-050545
- JSON: https://secwatch.observer/filing/0001628280-24-050545.json
- Plain text: https://secwatch.observer/filing/0001628280-24-050545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.